Comparison of Rigid and Non-Rigid Interbody Fusion Device for Cervical Degenerative Disc Disease in Adults

Phase 4

Recruiting

• Conditions: Cervical Disc Degeneration
• Interventions: Combination Product: Z-Brace interbody fusion device; Combination Product: PEEK interbody fusion device

• Registration Number: NCT04550923
• Lead Sponsor: National Taiwan University Hospital

Brief Summary

Rigid interbody fusion device in bulk configuration has been widely used in anterior cervical discectomy and fusion (ACDF) surgery. It is a randomized, prospective, multicenter clinical study to compare rigid and non-rigid fusion device in ACDF for cervical degenerative disc disease.

Detailed Description

This study is a randomized, prospective, multicenter clinical trial comparing rigid (PEEK) interbody fusion device with non-rigid (Titanium Alloy, Z-Brace, Baui Biotech) interbody fusion device in ACDF surgery at 11 clinical sites. ACDF was performed with stand-alone interbody fusion device and artificial bone graft (hydroxyapatite/tricalcium phosphate). Patients have 1-level or 2-level cervical degenerative disc disease approved for ACDF surgery by National Health Insurance, which is the blind, third-party, administrative approved and insurance reimbursement for surgical indication. Total 180 patients were enrolled, and 180 patients were randomized into either investigational device (non-rigid) group or the control (rigid) group in a 2:1 ratio. After confirming a patient's eligibility and having the patient sign an informed consent form, the site investigator or study coordinator call the coordinator at National Taiwan University Hospital for the randomization. Each patient will be then assigned to 1 of the treatment group according to a randomized schedule. Patient were evaluated preoperatively, one month postoperatively, and 3, 6, 12, 18, and 24 months postoperatively. Measured outcomes included overall success, Neck Disability Index (NDI), VAS neck and arm pain, adjacent range of motion, patient satisfaction, anxiety score, SF-12 MCS/PCS, major complications, subsequent surgery rate, and subsidence and fusion rate on radiological examinations. The primary endpoint was a FDA composite definition of success comprising clinical improvement and absence of major complications and secondary surgery events.

Study Timeline

• Study First Submitted: 2020-09-02
• Study First Submitted QC: 2020-09-09
• Study First Posted: 2020-09-16
• Study Start: 2020-12-03
• Primary Completion: 2023-06-30
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-23
• Last Update Posted: 2024-05-24
• Study Completion: 2025-06-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

1. Age 20 - 69 years;
2. Symptomatic cervical degenerative disc disease in one or two levels between C3-7 with radiculopathy or myeloradiculopathy and/or decrease muscle strength and/or abnormal sensation and/or abnormal reflexes;
3. Deficit confirmed by CT, MRI, or X-ray;
4. NDI Score of ≥ 30/100;
5. Unresponsive to non-operative treatment of at least 6 weeks or presence of progressive symptoms or signs of nerve root/spinal cord compression despite continued non-operative treatment;
6. No prior surgical procedures at the operative level and non-prior fusions at any cervical level;
7. Physically and mentally able and willing to comply with the protocol;
8. Signed informed consent;

Read More

Exclusion Criteria

1. Patient does not meet the indication of Anterior Cervical Discectomy and Fusion (ACDF), which is under the surveillance. (Surgical indication of ACDF is approved by National Health Insurance Administration Ministry of Health and Welfare, a blinded third-party authority).
2. More than two vertebral levels required surgery;
3. Immobile levels between C1 and C7 from any cause;
4. Any prior surgery at the operative level or any prior fusion at any cervical level;
5. T-score less than -1.5 (osteoporosis evaluation)
6. Paget's disease, osteomalacia, or any other metabolic bone disease other than osteoporosis;
7. Active infection of surgical site or history of anticipated treatment for systemic infection including HIV
8. Active malignancy: a history of any invasive malignancy (except carcinoma in situ and non-melanoma skin cancer), unless treated with curative intent with no clinical signs or symptoms of malignancy in the past 5 years;
9. Marked instability of the cervical spine on resting lateral or flexion-extension radiographs;
10. Known allergy to device materials including titanium or polyetheretherketone (PEEK);
11. Segmental kyphosis of greater than 11 degrees at treatment or adjacent levels
12. Rheumatoid arthritis, lupus, or other autoimmune disease;
13. Any diseases or conditions that would preclude accurate clinical evaluation;
14. Daily, high-dose oral and/or inhaled steroid or a history of chronic use of high dose steroids;
15. Body Mass Index (BMI) > 35
16. Smoking more than one pack of cigarettes per day;

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Investigational device (non-rigid) group	Z-Brace interbody fusion device	Use non-rigid (Titanium Alloy, Z-Brace, Baui Biotech) interbody fusion device.
Control device (rigid) group	PEEK interbody fusion device	Use rigid (PEEK) interbody fusion device .

Primary Outcome Measures

Name	Time	Method
Change from baseline Subsidence and Fusion rate	Patient were evaluated one month postoperatively, and 3, 6, 12, 18, and 24 months postoperatively.	Subsidence and fusion rate on radiological.
Change from baseline Adjacent range of motion	Patient were evaluated preoperatively, one month postoperatively, and 3, 6, 12, 18, and 24 months postoperatively.	Adjacent range of motion on radiological.
Change from baseline postoperative condition (if patients have major complications)	Patient were evaluated one month postoperatively, and 3, 6, 12, 18, and 24 months postoperatively.	No adverse events (AEs) classified as major complications by Research Ethics Committee.
Change from baseline postoperative condition (if patients have subsequent surgeries)	Patient were evaluated one month postoperatively, and 3, 6, 12, 18, and 24 months postoperatively.	No subsequent surgical intervention.
Change from baseline Neck Disability Index (NDI)	Patient were evaluated preoperatively, one month postoperatively, and 3, 6, 12, 18, and 24 months postoperatively.	An improvement in Neck Disability Index (NDI) score of at least 30 points for a patient with a preoperative NDI score of 60 or greater; or an improvement of at least 50% of preoperative NDI score for patients with a preoperative score of less than 60.

Secondary Outcome Measures

Name	Time	Method
Patient Satisfaction Questionnaire	Patient were evaluated one month postoperatively, and 3, 6, 12, 18, and 24 months postoperatively.	Patients will be surveyed by Patient Satisfaction Questionnaire. There are two questions on the questionnaire to evaluate if they are satisfied with their treatment and if they will recommend their respective surgery to a friend.
Visual analogue scale (neck and arm and chest pain)	Patient were evaluated preoperatively, one month postoperatively, and 3, 6, 12, 18, and 24 months postoperatively.	Patient will be evaluated by Visual analogue scale(VAS) for their neck, arm and chest pain.; The minimum value is 0 and the maximum value is 10. Higher score means a worse outcome.
Anxiety score	Patient were evaluated preoperatively, one month postoperatively, and 3, 6, 12, 18, and 24 months postoperatively.	The Beck Anxiety Inventory (BAI). The minimum value is 0 and the maximum value is 63. Higher scores mean a worse outcome.
Depression Score	Patient were evaluated preoperatively, one month postoperatively, and 3, 6, 12, 18, and 24 months postoperatively.	Beck Depression Inventory(BDI). The minimum value is 0 and the maximum value is 63. Higher scores mean a worse outcome.
Short form-12 mental component scale and physical component scale (SF-12 MCS/PCS) score	Patient were evaluated preoperatively, one month postoperatively, and 3, 6, 12, 18, and 24 months postoperatively.	Short form-12 mental component scale and physical component scale. The minimum value of physical component scale (PCS-12) is 18.4 and the maximum value of PCS-12 is 57.8. The minimum value of mental component scale (MCS-12) is 18.7 and the maximum value of MCS-12 is 65.2. Higher scores mean a better outcome.
Number of days using Non-steroidal anti-inflammatory analgesics(NSAIDs)	Patient were evaluated preoperatively, one month postoperatively, and 3, 6, 12, 18, and 24 months postoperatively.	Number of days using Non-steroidal anti-inflammatory analgesics(NSAIDs)

Trial Locations

Locations (13)

MacKay Memorial Hospital; 🇨🇳 Taipei City, Zhongshan, Taiwan

National Taiwan University Hospital Yunlin Branch; 🇨🇳 Douliu, Yunlin County, Taiwan

Fu Jen Catholic University Hospital; 🇨🇳 New Taipei City, Taishan District, Taiwan

National Taiwan University Hospital; 🇨🇳 Taipei, Zhongzheng Dist., Taiwan

National Taiwan University Hospital Hsin-Chu Branch; 🇨🇳 Hsinchu, Taiwan

Jen-Ai Hospital Dali Branch; 🇨🇳 Taichung, Taiwan

Taipei Municipal Wan Fang Hospital; 🇨🇳 Taipei City, Wenshan Dist., Taiwan

Chung Shan Medical University Hospital; 🇨🇳 Taichung, South Dist., Taiwan

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare; 🇨🇳 New Taipei, Zhonghe District, Taiwan

China Medical University Hospital; 🇨🇳 Taichung, Taiwan

National Cheng Kung University Hospital; 🇨🇳 Tainan, Taiwan

Min-Sheng General Hospital; 🇨🇳 Taoyuan, Taiwan

Chang Gung Memorial Hospital; 🇨🇳 Taoyuan, Taiwan